Literature DB >> 16281957

Benefits and risks of iron therapy for chronic anaemias.

G Weiss1, V R Gordeuk.   

Abstract

Iron is used widely for the treatment of anaemias with iron-restricted erythropoiesis. This intervention can be both beneficial and detrimental depending on the type of the underlying process. While in iron deficiency anaemia (IDA), the most frequent anaemia in the world, iron is the therapy of choice, this intervention can be harmful in the anaemia of chronic disease or anaemia associated with renal failure, the most common anaemias in hospitalized adult patients in Western countries. Iron is able to negatively affect cell-mediated immune effector mechanisms directed against invading microorganisms and tumour cells while at the same time, as an essential nutrient, it can stimulate the proliferation of these unwanted cells. In addition, iron catalyses the formation of toxic radicals leading to tissue damage or the promotion of cardiovascular events. Thus, it is essential to correctly diagnose the precise cause of anaemia and to consider the benefits and hazards of targeted iron therapy.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16281957     DOI: 10.1111/j.1365-2362.2005.01529.x

Source DB:  PubMed          Journal:  Eur J Clin Invest        ISSN: 0014-2972            Impact factor:   4.686


  12 in total

1.  Effects of intravenous iron saccharate on improving severe anemia in rheumatoid arthritis patients.

Authors:  Wei-Sheng Chen; Chun-Yu Liu; Hui-Ting Lee; Kelvin Tsai; Yi-Chun Lin; Der-Cherng Tarng; Chao-Hung Ho; Hsiao-Yi Lin
Journal:  Clin Rheumatol       Date:  2011-10-29       Impact factor: 2.980

Review 2.  Molecular and clinical aspects of iron homeostasis: From anemia to hemochromatosis.

Authors:  Manfred Nairz; Günter Weiss
Journal:  Wien Klin Wochenschr       Date:  2006-08       Impact factor: 1.704

3.  Synthesis of 5-dialkyl(aryl)aminomethyl-8-hydroxyquinoline dansylates as selective fluorescent sensors for Fe3+.

Authors:  Ruogu Peng; Feng Wang; Yaowu Sha
Journal:  Molecules       Date:  2007-05-31       Impact factor: 4.411

Review 4.  Does iron have a role in breast cancer?

Authors:  Xi Huang
Journal:  Lancet Oncol       Date:  2008-08       Impact factor: 41.316

Review 5.  The correction of anemia in patients with the combination of chronic kidney disease and congestive heart failure may prevent progression of both conditions.

Authors:  Donald S Silverberg; Dov Wexler; Adrian Iaina; Doron Schwartz
Journal:  Clin Exp Nephrol       Date:  2008-08-01       Impact factor: 2.801

6.  Effects of cellular iron deficiency on the formation of vascular endothelial growth factor and angiogenesis. Iron deficiency and angiogenesis.

Authors:  Jonathan Eckard; Jisen Dai; Jing Wu; Jinlong Jian; Qing Yang; Haobin Chen; Max Costa; Krystyna Frenkel; Xi Huang
Journal:  Cancer Cell Int       Date:  2010-08-19       Impact factor: 5.722

7.  Isocitrate ameliorates anemia by suppressing the erythroid iron restriction response.

Authors:  Chanté L Richardson; Lorrie L Delehanty; Grant C Bullock; Claudia M Rival; Kenneth S Tung; Donald L Kimpel; Sara Gardenghi; Stefano Rivella; Adam N Goldfarb
Journal:  J Clin Invest       Date:  2013-07-25       Impact factor: 14.808

Review 8.  The role of iron supplementation during epoietin treatment for cancer-related anemia.

Authors:  M Hedenus; G Birgegård
Journal:  Med Oncol       Date:  2008-05-13       Impact factor: 3.064

9.  Improving hepatitis B vaccine efficacy in end-stage renal diseases patients and role of adjuvants.

Authors:  Mohammad Hossein Somi; Babak Hajipour
Journal:  ISRN Gastroenterol       Date:  2012-09-18

Review 10.  Iron therapy for renal anemia: how much needed, how much harmful?

Authors:  Walter H Hörl
Journal:  Pediatr Nephrol       Date:  2007-01-06       Impact factor: 3.714

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.